1) Strategic Separation of Nutrition Business
- Abbott announced plans to separate its nutrition business into an independent, publicly traded company, aiming to enhance value for both entities.
- The decision follows a strategic review and reflects the evolving market dynamics in nutrition, which is increasingly influenced by consumer preferences.
- The new nutrition company, with approximately $8.5 billion in annual sales and a strong portfolio of brands, is expected to qualify for the S&P 500.
- Daniel Salvadori will lead the new nutrition company as CEO, supported by an experienced leadership team.
- Abbott will focus on higher growth, higher margin businesses post-separation, maintaining a balanced portfolio across MedTech, diagnostics, and Established Pharmaceuticals.

2) Q3 Financial Performance
- Abbott reported a 7% increase in sales and a 9% increase in earnings per share (EPS) for Q3 2026, marking an acceleration compared to the first half of the year.
- Diagnostics sales grew 6.5%, driven by core laboratory and cancer diagnostics, with cancer diagnostics specifically growing 14%.
- Nutrition sales increased by 5%, with pediatric nutrition growing 9% in the U.S. due to WIC contract wins.
- Established Pharmaceuticals (EP) sales rose 8.5%, reflecting strong growth in emerging markets.
- Medical devices saw an 8% growth, with notable performance in electrophysiology and rhythm management.

3) Challenges and Headwinds
- Abbott faced challenges in the EP segment due to market dynamics related to the left atrial appendage (LAA) market, impacting growth expectations.
- The diabetes care segment is experiencing pricing pressure and a slowdown in growth due to lack of new reimbursement expansions, particularly for continuous glucose monitoring (CGM) in type 2 diabetes patients.
- A cybersecurity incident in July affected the cancer diagnostics segment, leading to temporary drops in order volumes.

4) Operational and Product Plans
- Abbott continues to advance its innovation pipeline, with multiple product launches expected, including a new blood-based colorectal cancer screening test.
- The company is focused on maintaining a strong R&D investment, projected to exceed $3 billion this year, to support future growth.
- Upcoming product approvals include the Amulet 360 left atrial appendage device and the TactiFlex Duo catheter, which are expected to enhance market share in their respective segments.
- Abbott is also exploring tuck-in acquisitions to complement its portfolio while maintaining a balanced approach to capital allocation.

5) Guidance and Outlook
- For Q4 2026, Abbott expects adjusted EPS between $1.62 and $1.67, with a forecasted sales growth of approximately 8%.
- The company anticipates that the separation will lead to accelerated sales growth and improved profitability for both Abbott and the new nutrition company.
- Guidance for 2027 suggests a conservative approach, with expectations for continued EPS growth and margin expansion, but without specific figures provided at this time.

Bottom line: Abbott's strategic separation of its nutrition business is positioned to unlock value for shareholders, while the company continues to deliver solid financial performance and innovation across its diversified healthcare portfolio. The outlook remains cautiously optimistic, with a focus on growth and operational efficiency.